Drug resistance and minimal residual disease in multiple myeloma

Great progress has been made in improving survival in multiple myeloma (MM) patients over the last 30 years. New drugs have been introduced and complete responses are frequently seen. However, the majority of MM patients do experience a relapse at a variable time after treatment, and ultimately the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozzetti, Alessandro, Ciofini, Sara, Sicuranza, Anna, Pacelli, Paola, Raspadori, Donatella, Cencini, Emanuele, Tocci, Dania, Bocchia, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992600/
https://www.ncbi.nlm.nih.gov/pubmed/35582527
http://dx.doi.org/10.20517/cdr.2021.116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992600/
https://www.ncbi.nlm.nih.gov/pubmed/35582527
http://dx.doi.org/10.20517/cdr.2021.116

Ejemplares similares